# Health resource use and epidemiologic profile of herpes zoster outpatients aged 50 years or older: a modified Delphi consensus panel in Brazil

**Authors:** Ângela Maria Bagattini, Michelle Quarti Machado da Rosa, Jorge A. Gomez, Jamile Ballivian, Agustín Casarini, Ariel Bardach, Cristiana Maria Toscano

PMC · DOI: 10.1016/j.bjid.2025.104560 · The Brazilian Journal of Infectious Diseases · 2025-07-04

## TL;DR

This study examines the healthcare resource use and complications of herpes zoster in older adults in Brazil, highlighting the burden on the healthcare system.

## Contribution

The study provides new insights into HZ-related healthcare resource use and complications in Brazil using a Delphi consensus panel.

## Key findings

- HZ outpatients aged 80+ had 14% PHN, significantly higher than younger age groups.
- Absenteeism ranged from 30% to 68% depending on clinical presentation.
- Acyclovir and valaciclovir were the most commonly used therapies in public and private systems, respectively.

## Abstract

Herpes Zoster (HZ) and its complications, such as Postherpetic Neuralgia (PHN), are associated with significant burden in elderly. In Brazil, data on economic and epidemiologic HZ burden is still limited. We conducted a Delphi panel to assess healthcare resource use in HZ outpatients aged 50-years and older. Diagnosis and treatment resources, proportion of referral and hospitalization were estimated considering HZ, PHN, ophthalmic and neurologic zoster typical cases. A diverse group of 20 medical specialists was selected, and responded anonymously to an online questionnaire. Consensus was met if ≥ 75 % agreement was reached in the 1st round, and if not met, a 2nd round was held. Summary statistics are reported stratified by age-groups and healthcare system (public and private). Responses were obtained from 19 and 17 panel members in the 1st and 2nd rounds, respectively. The proportion HZ outpatients with PHN increased significantly with age (4 % in 50‒59; 14 % in ≥ 80 years). Ophtalmic and neurological complications ranged from 5 %‒13 % across age groups. Absenteeism was high, ranging from 30 %‒68 % of patients depending on the clinical presentation. HZ patients required 2‒3 medical visits, and referral to another medical specialty varied from 10 %‒22 % across age ranges, doubling for NPH patients. Proportion of hospitalization varied from 1–8 %. HZ diagnosis was mainly clinical (93 %). Acyclovir (95 %) and valaciclovir (80 %) were the therapy of choice in the public and private systems, respectively. Pain management included dipyrone and codeine (63 %), pregabalin (58 %), and gabapentin (Neurontin) (48 %). Our results report significant healthcare resource utilization by elderly HZ patients in Brazil.

## Linked entities

- **Chemicals:** Acyclovir (PubChem CID 135398513), valaciclovir (PubChem CID 135398742), dipyrone (PubChem CID 522325), codeine (PubChem CID 5284371), pregabalin (PubChem CID 4715169), gabapentin (PubChem CID 3446), Neurontin (PubChem CID 3446)
- **Diseases:** Herpes Zoster (MONDO:0005609), Postherpetic Neuralgia (MONDO:0041052)

## Full-text entities

- **Diseases:** HZ (MESH:D006562), Pain (MESH:D010146), NPH (MESH:D006850), neurological complications (MESH:D002493), PHN (MESH:D051474)
- **Chemicals:** Acyclovir (MESH:D000212), Neurontin (MESH:D000077206), valaciclovir (MESH:D000077483), pregabalin (MESH:D000069583), codeine (MESH:D003061), dipyrone (MESH:D004177)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12271774/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12271774/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12271774/full.md

---
Source: https://tomesphere.com/paper/PMC12271774